Eli Lilly's stock rises 2.7% to $1,188.72 amid positive clinical trial results.

Eli Lilly's stock experienced a 2.7% increase, closing at $1,188.72, following the announcement of positive results from the Phase 3 BRUIN CLL-314 clinical trial. The trial demonstrated that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in overall response rate compared to ibrutinib, with a numerically higher response rate of 87.0% versus 78.5%. Additionally, progression-free survival data trended favorably for pirtobrutinib, indicating a potential 43% reduction in the risk of disease progression or death.

AI-generated from public news sources. Not financial advice.